ITM aims to compete with Novartis after Phase 3 radiopharma win

ITM Iso­tope Tech­nolo­gies Mu­nich plans to seek ap­proval for its β-emit­ting ra­di­oli­gand in gas­troen­teropan­cre­at­ic neu­roen­docrine tu­mors (GEP-NETs) fol­low­ing a Phase 3 suc­cess, the biotech said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.